AstraZeneca has announced promising findings from a Phase III trial examining a novel liver cancer regimen. The combination of immunotherapies and targeted approaches, including IMFINZI, IMJUDO, lenvatinib, and transarterial chemoembolization (TACE), demonstrated a significant delay in disease progression.

China’s top health authority has granted Adcentrx Therapeutics approval to proceed with trials for ADRX-0405, an investigational STEAP1 antibody-drug conjugate aiming to treat late-stage solid tumors, including prostate cancer. Building on progress from its U.S. Phase 1a/1b study, the company aims to broaden the trial’s reach and accelerate patient enrollment by including clinical centers in China.

A growing tide of clinical research is transforming synovial sarcoma treatment prospects. According to DelveInsight Business Research LLP, over 15 pharmaceutical firms are developing more than 20 new therapies, reflecting a heightened commitment to tackling this rare cancer.

A proposed California bill aimed at reinforcing antitrust enforcement may also complicate the collaborative research that underpins clinical trials. One patient’s experience highlights what’s at stake—these trials saved her life, and she warns against endangering their vital role in advancing healthcare.

Volunteers in clinical trials for neurodegenerative diseases have been recognized for their remarkable contributions to Alzheimer’s and Parkinson’s research. This year’s award recipients embody the dedication needed to drive progress in finding effective therapies and raising community awareness.

Truveta has unveiled a groundbreaking clinical trials solution, offering sponsors real-time access to daily refreshed US health data. By speeding patient identification and enrollment, the platform promises to reduce delays in developing new therapies.

AbbVie is set to acquire Gilgamesh Pharmaceuticals’ bretisilocin, a next-generation psychedelic compound with promising Phase 2 results for major depressive disorder. The treatment’s short-acting properties and robust clinical data highlight its potential to address critical gaps in current psychiatric therapies.

Liminatus Pharma is set to advance IBA101, a next-generation CD47 inhibitor designed to avoid the severe side effects that halted previous therapies, into human trials in the U.S. and Korea by early 2027. This innovative drug promises to redefine cancer immunotherapy by targeting tumors while sparing healthy cells, potentially offering new hope to patients.

Promising advances in immunotherapy may allow some cancer patients to bypass chemotherapy, radiation, and surgery. New clinical trial findings reported by Dr. Jon LaPook suggest a groundbreaking shift in cancer treatment, offering renewed hope to many.

Context Therapeutics has reported its fiscal year 2024 results, highlighting significant strides in cancer immunotherapy. With strategic acquisitions and a strengthened financial position, the biotech firm is poised to advance its pipeline of T cell engaging bispecific antibodies targeting solid tumors.